- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-6307
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis ; volume:20 ; number:10 ; day:9 ; month:8 ; year:2018 ; pages:1-10 ; date:10.2018
Current rheumatology reports ; 20, Heft 10 (9.8.2018), 1-10, 10.2018
- Creator
-
Zhao, Sizheng
- Contributor
-
Chadwick, Laura
Mysler, Eduardo
Moots, Robert J.
SpringerLink (Online service)
- DOI
-
10.1007/s11926-018-0769-6
- URN
-
urn:nbn:de:101:1-2018102921375223392831
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhao, Sizheng
- Chadwick, Laura
- Mysler, Eduardo
- Moots, Robert J.
- SpringerLink (Online service)
Other Objects (12)
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
AVT02: An Adalimumab Biosimilar
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Correction to: AVT02: An Adalimumab Biosimilar
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
AVT02: An Adalimumab Biosimilar
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Correction to: AVT02: An Adalimumab Biosimilar
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
AVT02: An Adalimumab Biosimilar
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Correction to: AVT02: An Adalimumab Biosimilar
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis